Back to Results
Michael J Burke
Request an appointment
 Watch video

Michael J Burke, MD

Pediatric Hematology-Oncology, Pediatrics
Children’s Wisconsin since 2013
  • Pediatric cancer specialist, Children's Wisconsin
  • Professor, Medical College of Wisconsin

Locations

Overview

Services

Dr. Michael Burke is an Associate Professor at Children’s Wisconsin in the Division of Hematology/Oncology. He is Director of the Pediatric Leukemia & Lymphoma Program at Children's and Co-Director of the Developmental Therapeutics Program where he oversees all early phase clinical trials (Phase I and II studies) at Children's. He has developed both early phase and upfront clinical trials in acute leukemia that have opened locally here at Children's Wisconsin as well as nationally and internationally through consortiums such as the Children’s Oncology Group (COG) and the Therapeutic Advances in Childhood Leukemia & Lymphoma Consortium (TACL). Dr. Burke is the principal investigator of a Phase I trial for relapsed ALL and a phase I trial in relapsed AML both through the TACL consortium as well as study chair for the upfront COG trial for children with High-Risk and Very High-Risk B-cell ALL.

Dr. Burke’s research interests have focused on reporting clinical outcomes for both children and adults with high-risk leukemia for which he has over 30 publications as well as the development of early phase clinical trials investigating novel agents and/or combination therapies for relapsed/refractory acute leukemia. He did his pediatric residency at the Medical College of Virginia /Virginia Commonwealth University in Richmond Virginia and pediatric fellowship training in hematology-oncology at Northwestern University Lurie Children’s Hospital in Chicago, Illinois.

Certifications

  • Pediatric Hematology-Oncology, Pediatrics

Areas of Interest

  • Cancer
  • Leukemia
  • Lymphoma
  • Leukemia relapsed
  • Clinical trials
Show less... Show more...

Education and Awards

Education

  • 2000, Ross University School of Medicine (West Indies), MD

Residencies

  • 2003, Virginia Commonwealth University - Pediatrics

Fellowships

  • 2006, McGaw Med Ctr of Northwestern Univ - Ped Hem/Onc

Awards

  • Best Doctors in America 

National elected/appointed leadership and committee positions

  • 2016- Present Ad-Hoc Consultant for Oncologic Drug Advisory Committee (ODAC), U.S. Food and Drug Administration (FDA)
  • 2015- Present Study Chair, Phase Ib Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia, TACL/AMGEN
  • 2015- Present Committee Member, Chronic Myeloid Leukemia (CML) Working Group, Children's Oncology Group (COG)
  • 2015- Present Committee Member, Acute Lymphoblastic Leukemia (ALL) Clinical Studies, American Society of Hematology (ASH) Meeting Abstract Reviewer
  • 2015- Present Abstract Reviewer, Acute Lymphoblastic Leukemia (ALL) Clinical Studies, American Society of Hematology (ASH) Meeting
  • 2013- Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Onyx Pharmaceuticals
  • 2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Jazz Pharmaceutical
  • 2013- Present Member/PI, TACL MCW Institutional PI, Medical College of Wisconsin
  • 2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Seattle Genetics Inc.
  • 2012 - Present Member, TACL Steering & Prioritization Committee, Medical College of Wisconsin
  • 2012 - Present Member, TACL Steering Committee, Medical College of Wisconsin
  • 2011- Present Study co-chair, AALL1131 A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789) NSC#606869) in the Very High Risk Stratum, Children’s Oncology Group (COG)
  • 2010- 2013 Study Chair, ADVL0911 Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-011), Children’s Oncology Group (COG)
  • 2010- 2012 Committee Member, ALL Relapse Task Force, Children’s Oncology Group (COG)
  • 2009 - Present Study Chair, TACL T2009-003, A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
  • 2008 - 2012 Committee Member, Oncology Strategy Group
  • 2007- 2013 Committee Member, ALL Working Group, Center for International Blood and Marrow Transplant Research (CIBMTR)
  • 2007 - 2013 Committee Member, Pediatric Cancer Working Group, Center for International Blood and Marrow Transplant Research (CIBMTR)
  • 2007- 2013 Committee Member and ALL Liaison, Young Investigators Committee, Children's Oncology Group (COG)
  • 2007 - Present Committee Member, High Risk ALL, Children's Oncology Group (COG)

Journal Review

  • New England Journal Of Medicine
  • Leukemia Research Reports
  • Clinical Advances in Hematology and Oncology
  • Clinical Pharmacology
  • Journal of Clinical Medicine
  • Annals of Transplantation
  • Biology of Blood and Marrow Transplantation
  • International Journal of Nanomedicine
  • Leukemia and Lymphoma
  • Pediatric Blood and Cancer
  • Advances and Applications
  • Leukemia
  • Frontiers in Oncology
  • Blood
  • Current Cancer Drug Targets
  • Journal of Pediatric Hematology and Oncology
  • British Journal of Cancer

Research and publications

Publications